Chemotherapy-induced heart failure of HER-2 Positive breast cancer: a scoping review
DOI:
https://doi.org/10.33448/rsd-v11i9.31830Keywords:
Heart Failure; HER-2 Genes; Breast cancer; Stroke volume.Abstract
Breast cancer is the neoplasm that most affects women worldwide. Among the most established treatments for this pathology, and especially for the immunohistochemical subtype with overexpression of the Her-2 protein, is the use of chemotherapeutic agents, especially antineoplastic antibiotics and monoclonal drugs. However, these therapies can induce cardiotoxicity and heart failure events. The present study aims to evaluate aspects related to the development of heart failure resulting from chemotherapy treatment for Her-2 positive breast cancer. For this Scope Review, carried out through the PubMed and Science Direct platforms between 2020 and 2022, the descriptors chosen were ''Heart Failure'',''Breast Cancer'', ''Her-2'' and ''Ejection Fraction' ', associated with the boolean operator ''AND''. Inclusion criteria consisted of 1) clinical trials, controlled and randomized trials, reviews and meta-analyses; 2) studies on the induction of heart failure resulting from treatment for Her-2 positive breast cancer, 3) studies that evaluated the damage caused by cardiotoxicity, and 4) articles on the clinical management of heart failure. Exclusion criteria consisted of inadequacies to the topic, case reports and studies with animals, in addition to texts outside the time limit. It was observed that heart failure after the use of chemotherapy acted as a predictor of severe morbidity and mortality. Adverse events resulting from the use of antineoplastic drugs for Her-2 positive breast cancer ranged from a drop in ejection fraction to sudden death. The discontinuation of these drugs still remains a topic to be elucidated, as well as the application of cardioprotection strategies.
References
Al-Sadawi, M., Hussain, Y., Copeland-Halperin, R. S., Tobin, J. N., Moskowitz, C. S., Dang, C. T., ... & Anthony, F. Y. (2021). Racial and Socioeconomic Disparities in Cardiotoxicity Among Women With HER2-Positive Breast Cancer. Am. J. Cardiol., 147, 116-121.
Anjos, M., Fontes-Oliveira, M., Costa, V. M., Santos, M., & Ferreira, R. (2021). An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity. Life Sci., 280, 119760.
Battisti, N. M. L., Joshi, K., Nasser, M. S., & Ring, A. (2021). Systemic therapy for older patients with early breast cancer. Cancer Treat. Rev., 100, 102292.
Blaes, A., Manisty, C., & Barac, A. (2020). How to follow, manage and treat cardiac dysfunction in patients with Her2+ breast cancer. Cardio Oncology, 2(4), 661-665.
Blancas, I., Martín-Pérez, F. J., Garrido, J. M., & Rodríguez-Serrano, F. (2020). NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast, 54, 106-113.
Bolli, R., Perin, E. C., Willerson, J. T., Yang, P. C., Traverse, J. H., Henry, T. D., & Cardiovascular Cell Therapy Research Network (CCTRN). (2020). Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial. Cardio Oncology, 2(4), 581-595.
Bouwer, N. I., Jager, A., Liesting, C., Kofflard, M. J., Brugts, J. J., Kitzen, J. J., & Levin, M. D. (2020). Cardiac monitoring in HER2-positive patients on trastuzumab treatment: a review and implications for clinical practice. Breast, 52, 33-44.
Calvillo-Argüelles, O., Abdel-Qadir, H., Suntheralingam, S., Michalowska, M., Amir, E., & Thavendiranathan, P. (2020). Trastuzumab-related cardiotoxicity and cardiac care in patients with hER2 positive metastatic breast cancer. Am. J. Cardiol., 125(8), 1270-1275.
Demissei, B. G., Adusumalli, S., Hubbard, R. A., Denduluri, S., Narayan, V., Clark, A. S., & Ky, B. (2020). Cardiology involvement in patients with breast cancer treated with trastuzumab. Cardio Oncology, 2(2), 179-189.
Dempsey, N., Rosenthal, A., Dabas, N., Kropotova, Y., Lippman, M., & Bishopric, N. H. (2021). Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res. Treat., 188(1), 21-36.
De Sanctis, R., Giordano, L., D’Antonio, F., Agostinetto, E., Marinello, A., Guiducci, D., & Santoro, A. (2021). Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant sc versus iv trastuzumab. Breast, 57, 80-85.
Diaz, L. S. P., Schuman, M. L., Aisicovich, M., Toblli, J. E., Pirola, C. J., Landa, M. S., & García, S. I. (2020). Short-term doxorubicin cardiotoxic effects: involvement of cardiac Thyrotropin Releasing Hormone system. Life Sci., 261, 118346.
Dobson, R., Ghosh, A. K., Ky, B., Marwick, T., Stout, M., Harkness, A., & British Society of Echocardiography (BSE) and theBritish Society of Cardio-Oncology (BCOS). (2021). BSE and BCOS Guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Cardio Oncology, 3(1), 1-16.
dos Santos Cesário, J. M., de Paula Flauzino, V. H., de Oliveira Hernandes, L., Gomes, D. M., & da Silva Vitorino, P. G. (2021). Assistência de enfermagem aos pacientes com cardiotoxicidade induzidas por quimioterápicos. RSD, 10(6), e34210615355-e34210615355.
Eiger, D., Franzoi, M. A., Pondé, N., Brandão, M., De Angelis, C., Nogueira, M. S., & de Azambuja, E. (2020). Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. ESMO open., 5(1), e000659
Fernandes, A. D., Fernandes, G. C., Mazza, M. R., Knijnik, L. M., Fernandes, G. S., Vilela, A. T. D., & Chaparro, S. V. (2020). Insuficiência cardíaca no Brasil subdesenvolvido: análise de tendência de dez anos. Arq. Bras. Cardiol., 114, 222-231.
Ghasemi, K., Vaseghi, G., & Mansourian, M. (2021). Pharmacological interventions for preventing anthracycline-induced clinical and subclinical cardiotoxicity: A network meta-analysis of metastatic breast cancer. J. Oncol. Pharm. Pract., 27(2), 414-427.
Hajjar, L. A., Costa, I. B. S. D. S. D., Lopes, M. A. C. Q., Hoff, P. M. G., Diz, M. D. P. E., Fonseca, S. M. R., & Kalil, R. (2020). Diretriz Brasileira de Cardio-oncologia–2020. Arq. Bras. Cardiol., 115, 1006-1043.
He, X., Dai, X., Ji, J., Liu, H., Shi, G., & Yeung, S. C. J. (2022). Nine-Year Median Follow-up of Cardiotoxicity and Efficacy of Trastuzumab Concurrently with Anthracycline-Based and Anthracycline-Free Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer Patients. Clin. Breast Cancer, 22(1), e80-e90.
Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2020: incidência de câncer no Brasil. Rio de Janeiro: INCA; 2019
Karlstaedt, A., Barrett, M., Hu, R., Gammons, S. T., & Ky, B. (2021). Cardio-oncology: Understanding the intersections between cardiac metabolism and cancer biology. JACC Basic Transl Sci., 6(8), 705-718.
Kolberg, H. C., Colleoni, M., Demetriou, G. S., Santi, P., Tesch, H., Fujiwara, Y., ... & Hanes, V. (2020). Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the randomized, double-blind, active-controlled LILAC study. Drug Saf, 43(3), 233-242.
Koulaouzidis, G., Yung, A. E., Yung, D. E., Skonieczna-Żydecka, K., Marlicz, W., Koulaouzidis, A., & Charisopoulou, D. (2021). Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: Systematic review and meta-analysis. Curr Probl Cancer, 45(5), 100723.
Maddox, T. M., Januzzi Jr, J. L., Allen, L. A., Breathett, K., Butler, J., Davis, L. L., ... & Youmans, Q. R. (2021). 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J. Am. Coll. Cardiol., 77(6), 772-810.
Martha, J. W., Soedarsono, D. A., Iqbal, M., Astuti, A., Martanto, E., Akbar, M. R., & Sumantra, I. G. (2020). The effect of prophylactic carvedilol on subclinical left ventricular dysfunction after 1 cycle FAC chemotherapy in breast cancer patients. IJC Heart Vasc., 29, 100575.
Mazzutti, G. (2021). Cardiotoxicidade associada ao tratamento do câncer de mama: o papel do ventrículo direito.
Nack, E., Koffer, P. P., Blumberg, C. S., Leonard, K. L., Huber, K. E., Fenton, M. A., ... & Hepel, J. T. (2020). New cardiac abnormalities after radiotherapy in breast cancer patients treated with Trastuzumab. Clin. Breast Cancer, 20(3), 246-252.
Öztürk, C., Validyev, D., Becher, U. M., Weber, M., Nickenig, G., & Tiyerili, V. (2021). A novel scoring system to estimate chemotherapy-induced myocardial toxicity: risk assessment prior to non-anthracycline chemotherapy regimens. IJC Heart Vasc., 33, 100751.
Padegimas, A., Clasen, S., & Ky, B. (2020). Cardioprotective strategies to prevent breast cancer therapy-induced cardiotoxicity. Trends Cardiovasc. Med., 30(1), 22-28.
Pecoraro, M., Pinto, A., & Popolo, A. (2020). Trastuzumab-induced cardiotoxicity and role of mitochondrial connexin43 in the adaptive response. Toxicol In Vitro, 67, 104926.
Rawat, P. S., Jaiswal, A., Khurana, A., Bhatti, J. S., & Navik, U. (2021). Doxorubicin-induced cardiotoxicity: An update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed. Pharmacother., 139, 111708.
Rohde, L. E. P., Montera, M. W., Bocchi, E. A., Clausell, N. O., Albuquerque, D. C. D., Rassi, S., ... & Martins, W. D. A. (2018). Diretriz brasileira de insuficiência cardíaca crônica e aguda. Arq. Bras. Cardiol., 111(3), 436-539.
Schettini, F., Pascual, T., Conte, B., Chic, N., Brasó-Maristany, F., Galván, P., ... & Prat, A. (2020). HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. Cancer Treat. Rev., 84, 101965.
Schoffel, A., Thavendiranathan, P., Patrikar, A., Lee, D., & Abdel-Qadir, H. M. (2022). HEART FAILURE CARE AFTER EARLY-STAGE BREAST CANCER: A POPULATION-BASED MATCHED COHORT STUDY. J. Am. Coll. Cardiol., 79(9_Supplement), 1906-1906.
Tan, A. R., Im, S. A., Mattar, A., Colomer, R., Stroyakovskii, D., Nowecki, Z., ... & FeDeriCa study group. (2021). Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study. Lancet Oncol., 22(1), 85-97.
Wang, J., Niu, S., Dong, W., Wei, L., Ou, L., Zhang, T., ... & Fang, Y. (2020). A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Expert Opin Investig Drugs, 29(7), 755-762.
Wang, Y., Yin, X., Liang, X., Chen, Y., Pan, S., Chen, Z., ... & Liu, T. (2021). Three-dimensional vectorcardiographic characteristics of breast cancer patients treated with chemotherapy. J Electrocardiol., 67, 23-30.
Wedam, S., Fashoyin-Aje, L., Gao, X., Bloomquist, E., Tang, S., Sridhara, R., ... & Beaver, J. A. (2020). FDA approval summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin. Cancer Res., 26(16), 4180-4185.
Yu, A. F., Moskowitz, C. S., Lee Chuy, K., Yang, J., Dang, C. T., Liu, J. E., ... & Steingart, R. M. (2020). Cardiotoxicity surveillance and risk of heart failure during HER2 targeted therapy. Cardio Oncology, 2(2), 166-175.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Trinnye Luizze Santos; Walquiria da Silva Pedra Parreira; José Alencar Formiga Júnior; Jonathan Ballico de Moraes; Wild Kern Vieira Diniz ; Jaqueline Giselle Farias Fernandes; Michelle de Lima Brito Moura; Enzo Macêdo Nunes; Alyssa Castelo Branco Alencar Andrade
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
